Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.56 |
| ▸ | APP | P05067 | 11/20 | 0.56 |
| ▸ | BCHE | P06276 | 9/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125330 | 1.00 | ACHE (0.56) | ACHEAPPBCHECYP1A2CYP3A4 | |
| SCHEMBL30125335 | 0.94 | ACHE (0.54) | ACHEAPPBCHECYP1A2CYP3A4 | |
| SCHEMBL23723458 | 0.94 | ACHE (0.54) | ACHEAPPBCHECYP1A2CYP3A4 | |
| SCHEMBL30125157 | 0.87 | APP (0.58) | ACHEAPPBCHENPY1RNPY5R | |
| SCHEMBL23723420 | 0.87 | APP (0.58) | ACHEAPPBCHENPY1RNPY5R | |
| SCHEMBL26646037 | 0.87 | APP (0.57) | ACHEAPPBCHENPY1RNPY5R | |
| SCHEMBL23723491 | 0.86 | APP (0.56) | ACHEAPPBCHENPY1RNPY5R | |
| SCHEMBL30125344 | 0.86 | APP (0.56) | ACHEAPPBCHENPY1RNPY5R | |
| SCHEMBL23723455 | 0.85 | APP (0.56) | ACHEAPPBCHENPY1RNPY5R | |
| SCHEMBL23748933 | 0.85 | APP (0.55) | ACHEAPPBCHENPY1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | ACHE 1215/4885APP 4864/4885BCHE 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.